ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

SAVOR: The Onglyza CV outcomes study

SAVOR: Secondary composite endpoint

Secondary composite endpoint: CV death; myocardial infarction; ischaemic stroke; hospitalisation of unstable angina, coronary revascularisation or heart failure1

Secondary composite endpoint
Secondary composite endpoint

An increase in hospitalisation for heart failure (HHF) was observed in the Onglyza group compared to placebo (3.5% vs. 2.8%, respectively p=0.007)

1. Scirica BM et al. N Engl J Med 2013; 360: 1317-1326.